Dual Targeting of Nfs1 and Discovery of Its Novel Processing Enzyme, Icp55

Received for publication, June 17, 2009, and in revised form, August 11, 2009. Published, JBC Papers in Press, August 31, 2009, DOI 10.1074/jbc.M109.034694

Adi Naamati†1, Neta Regev-Rudzki†1, Shlomi Galperin‡, Roland Lill‡2,3, and Ophry Pines‡3,4

From the ‡Department of Microbiology and Molecular Genetics, IMRIC, Faculty of Medicine, Hebrew University, Jerusalem 91120, Israel and the §Institut of Cytobiology and Cytopathology, Philippus University, Marburg 35033, Germany

In eukaryotes, each subcellular compartment harbors a specific group of proteins that must accomplish specific tasks. Nfs1 is a highly conserved mitochondrial cysteine desulfurase that participates in iron-sulfur cluster assembly as a sulfur donor. Previous genetic studies, in Saccharomyces cerevisiae, have suggested that this protein distributes between the mitochondria and the nucleus with biochemically undetectable amounts in the nucleus (termed “eclipsed distribution”). Here, we provide direct evidence for Nfs1 nuclear localization (in addition to mitochondria) using both α-complementation and subcellular fractionation. We also demonstrate that mitochondrial and nuclear Nfs1 are derived from a single translation product. Our data suggest that the Nfs1 distribution mechanism involves at least partial entry of the Nfs1 precursor into mitochondria, and then retrieval of a minor subpopulation (probably by reverse translocation) into the cytosol and then the nucleus. To further elucidate the mechanism of Nfs1 distribution we determined the N-terminal mitochondrial sequence of Nfs1 by Edman degradation. This led to the discovery of a novel mitochondrial processing enzyme, Icp55. This enzyme removes three amino acids from the N terminus of Nfs1 after cleavage by mitochondrial processing peptidase. Intriguingly, Icp55 protease (like its substrate Nfs1) appears to be dual distributed between the nucleus and mitochondria.

The protein NifS was first identified and characterized in Azotobacter vinelandii, as part of the nitrogen fixation (nif) operon (4). This enzyme is a pyridoxal 5'-phosphate-dependent cysteine desulfurase. In eukaryotes, an NifS-like protein termed Nfs1 has been identified, which shows a highly conserved sequence homology. The Saccharomyces cerevisiae mitochondrial Nfs1 has been shown to participate in iron-sulfur cluster assembly (5). Nakai and coworkers identified an NLS5-like sequence, RRRPR, in the mature sequence of yeast Nfs1, that is highly conserved in eukaryotic Nfs1 proteins (e.g. in yeast, mouse, and human) (6). When this NLS5-like sequence was mutated to RRGSR, the mutant gene could not complement cell growth of a chromosomal NFS1-depleted strain. Nevertheless, this mutation did not affect the function of Nfs1 in the biogenesis of iron-sulfur proteins (5, 6). Nfs1 performs an additional function in the post-transcriptional modification of mitochondrial and cytosolic tRNAs (7). However, recent evidence suggests that nuclear Nfs1 does not serve as the sulfur donor for cytosolic tRNAs (8).

In S. cerevisiae and in human cells, Nfs1 cysteine desulfurases are encoded by single genes. The sorting mechanism that governs the simultaneous distribution of this protein into several subcellular compartments is unknown. In yeast, attempts to detect the endogenous Nfs1 in the nucleus by immunoblotting or immunofluorescence failed (6, 9, 10) most probably because Nfs1 is present at extremely low (eclipsed) levels in the nucleus. In human cells, the subcellular distribution of transiently expressed Nfs1 in mitochondria, cytosol, and nucleus was claimed to be achieved by alternative translation initiation from a single transcript (11). As described for yeast Nfs1, the low native amounts of extramitochondrial mammalian Nfs1 hampered its physical detection in the nucleus (5, 10, 12).

In this study, we characterized the processing pathway of yeast Nfs1 during its translocation into the mitochondrial matrix. To our surprise, we discovered that yeast Nfs1 undergoes two steps of proteolytic processing; first it is cleaved by the mitochondrial processing peptidase (MPP), which removes its mitochondrial targeting sequence (MTS) and then it is cleaved by a newly discovered peptidase, designated Icp55, which removes three amino acids from its N terminus. In addition, we used an α-complementation assay to detect the nuclear localization of Nfs1, and we provide evidence that the mitochondrial

† Both authors contributed equally to this work.
‡ Supported by the Deutsche Forschungsgemeinschaft (Grants SFB 593 and TR1, Gottfried-Wilhelm Leibniz program, and Grant GRK 1216), Rhön Klinikum AG, von Behring-Röntgen Stiftung, Max-Planck Gesellschaft, and Fonds der chemischen Industrie.
§ Supported by the Israel Science Foundation and The Niedersachsen-Israeli Research Cooperation. To whom correspondence should be addressed: Dept. of Molecular Biology, Hebrew University Medical School, Jerusalem 91120, Israel. Tel.: 972-2-675-7203; Fax: 972-2-675-7260; E-mail: ophryp@ekmd.huji.ac.il.

5 The abbreviations used are: NLS, nuclear localization sequence; X-gal, 5-bromo-4-chloro-3-indolyl-β-d-galactopyranoside; MPP, mitochondrial processing peptidase; MTS, mitochondrial targeting sequence; CCCP, carbonyl cyanide m-chlorophenylhydrazone; HxK1, hexokinase 1; WT, wild type.
and nuclear Nfs1 isoforms are derived from a single translation product.

**EXPERIMENTAL PROCEDURES**

**Strains, Plasmids, and Growth Conditions**

*Strains—* *S. cerevisiae* strains used were *BY4741* (Mata; his3Δ1; leu2Δ0; met15Δ0; ura3Δ0), *W303B1* (Mata; leu2–3,112; trpl–1; can1–100; ura3–1; ade2–1; his3–11,15), Δicp55 (Δyer078c; derived from a *W303B1* strain and was kindly provided by Thomas Langer (13)), and Tet-NFS1 (pNFS1::kanR-tet07-TATAURA3::CMV-tTA; MATa; his3–1; leu2–0; met15–0) (14).

*Plasmids Constructs—* *NFS1* gene was amplified using yeast genomic DNA as template by PCR using the indicated oligonucleotides (Table 1) and was cloned into vector p425Gal10 (15). All mutations were created using the QuikChange II kit (Stratagene) or PCR reactions using either the indicated oligonucleotides (Table 1). Nfs1-α was created as was described elsewhere (16) pHXK-α, pKG2-β, cytosolic ω (ωc), and mitochondrial ω (ωm) were also described elsewhere (16). Nuclear ω (ωNLS)-LacZ ω fragment was amplified from p0oc template using the indicated primers (Table 1); the reverse primer harbors the SV40-T antigen NLS (17), and the PCR product was cloned into pRS426-Met25 vector.

*Growth Conditions—* Strains harboring the appropriate plasmids were grown overnight at 30 °C in synthetic depleted (SD) medium containing 0.67% (w/v) yeast nitrogen base 2% galactose or 2% glucose (w/v), supplemented with the appropriate amino acids (50 μg/ml). For agar plates, 2% agar was added and when indicated 0.08% X-gal was added, dissolved in 100% N,N-dimethylformamide and phosphate buffer (25 mM sodium phosphate buffer titrated to pH 7.0). Plates containing 2% yeast extract, 1% peptone, and 2% glucose (w/v) (YPD) supplemented with 120 μg/ml tetracycline where used for conditional knock-out of Nfs1 for the Tet-NFS1 strain.

**Metabolic Labeling**

Cultures or induced cultures (in galactose) were harvested and labeled with 10 μCi/ml [35S]methionine and further incubated for 30 min at 30°C. When required, 20 μM carbonyl cyanide m-chlorophenylhydrazone (CCCP) was added before labeling. Labeling was stopped by addition of 10 mM sodium azide. Labeled cells were collected by centrifugation, resuspended in Tris/EDTA buffer, pH 8.0, containing 1 mM phenylmethylsulfonyl fluoride, broken with glass beads for 5 min, and centrifuged to obtain the supernatant fraction. Supernatants were denatured by boiling in 1% SDS, immunoprecipitated with anti-Nfs1 or anti-α rabbit antiserum and protein A-Sepharose (Amersham Biosciences), and then analyzed by SDS-PAGE.

**Subcellular Fractionation**

Induced yeast cultures were grown to an absorbance (A) of 1.5 at 600 nm. Mitochondria were isolated as described previously (18). Spheroplasts were prepared in the presence of Zymolyase-20T (MP Biomedicals, Irvine, CA). Each of our subcellular fractionation experiments was assayed for cross-contaminations by using anti-Aco1 antibody as a mitochondrial

**TABLE 1**

| Mutant name | Forward | Reverse |
|-------------|---------|---------|
| Nfs1-M85L   | GGATCCATGTTGAAATCAACTGCTAC | AAGCTTTCAATGACCTGACCATTTGATG |
| Nfs1-Shift  | GGATCCATGTTGAAATCAACTGCTAC | AAGCTTTCAATGACCTGACCATTTG |
| Nfs1-6His   | GGATCCATGTTGAAATCAACTGCTAC | AAGCTTTCAATGACCTGACCATTTGATG |
| Nfs1-M85L   | GCTGCGACCTCTCTATTTGGATGTGCAAGCTAC | GTAGCTTGCACATCCAAATAGAGAGTGCAGC |
| Nfs1-UP     | GGGCTTGTTTGGTAAGCGGAGAATTCTATTCCCCTCCTGCAGCAGGCG | CCGCTGCTGCAGGAGGGGAAAGGAATCTCCTGCTTACCAAAC |
| Nfs1-M85L   | GCTGCGACCTCTCTATTTGGATGTGCAAGCTAC | GTAGCTTGCACATCCAAATAGAGAGTGCAGC |
| Nfs1-UP     | GGGCTTGTTTGGTAAGCGGAGAATTCTATTCCCCTCCTGCAGCAGGCG | CCGCTGCTGCAGGAGGGGAAAGGAATCTCCTGCTTACCAAAC |
| Nfs1-Y34L   | GTTTGGTAAGCAGGAGATTCCTTTTCCCCTCCTGCAGCAGGC | GCCTGCTGCAGGAGGGGAAAAGGATCTCCTGCTTACCAAAC |
| Nfs1-F33S,Y35F | GTTTGGTAAGCAGGAGATTCTATTCCCCTGCTGCAGCAGGC | GCCTGCTGCAGGAGGGGAAAAGGATCTCCTGCTTACCAAAC |
| Nfs1-P37A   | GTTTGGTAAGCAGGAGATTCTATTCCGCTCCTGCAGCAGGCGTGAAGTTAGCTAACTTCACGCCTGCTGCAGCAGGGGAATAGAATCTCCTGCTTACC |
| Nfs1-P36A   | GTTTGGTAAGCAGGAGATTCTATTCCGCTCCTGCAGCAGGCGTGAAGCTTCACGCCTGCTGCAGGAGCGGAATAGAATCTCCTGCTTACC |
| Nfs1-P36D,P37D | GTTTGGTAAGCAGGAGATTCTATTCCGATGATGCAGCAGGCGTGAAGTTAGCTAACTTCACGCCTGCTGCATCATCGGAATAGAATCTCCTGCTTACC |
| Nfs1-P36A   | GTTTGGTAAGCAGGAGATTCTATTCCGCTCCTGCAGCAGGCGTGAAGCTTCACGCCTGCTGCAGGAGCGGAATAGAATCTCCTGCTTACC |
| Nfs1-P36D   | GTTTGGTAAGCAGGAGATTCTATTCCGATGATGCAGCAGGCGTGAAGTTAGCTAACTTCACGCCTGCTGCATCATCGGAATAGAATCTCCTGCTTACC |
| Nfs1-P36A   | GTTTGGTAAGCAGGAGATTCTATTCCGCTCCTGCAGCAGGCGTGAAGCTTCACGCCTGCTGCAGGAGCGGAATAGAATCTCCTGCTTACC |
| Nfs1-P36D   | GTTTGGTAAGCAGGAGATTCTATTCCGATGATGCAGCAGGCGTGAAGTTAGCTAACTTCACGCCTGCTGCATCATCGGAATAGAATCTCCTGCTTACC |
**Nfs1 Distribution and Its Processing Enzyme, Icp55**

marker and anti-hexokinase 1 (anti-HxK1) antibody as a cytosolic marker.

For isolation of nucleus, 200 ml of induced yeast culture was grown to 1.5 A at 600 nm. Cells were centrifuged at 5000 × g for 6 min and washed with phosphate-citrate buffer (pH = 6.5). Cells were digested to spheroplasts by Zymolyase-20T (MP Biomedicals, Irvine, CA). Spheroplasts were then precipitated at 1200 × g for 5 min and resuspended in lysis buffer (50 mM EDTA, 50 mM Tris–HCl, pH 7.6, 1% Triton X-100). Cells debris were centrifuged at 200 × g for 10 min at 4 °C, twice. Total sample was taken before nucleus precipitation. Nuclei were precipitated at 1500 × g for 20 min and then washed in the lysis buffer without Triton X-100. Nuclei were lysed with a high salts concentration buffer (20 mM Hepes, pH 7.6, 25% glycerol, 420 mM NaCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride). Samples were centrifuged at 14,000 × g for 20 min to remove nucleus debris and DNA. Total and nuclear fractions were assayed with anti-histone H4 antibody, which was kindly provided by Amikam Cohen (Hebrew University of Jerusalem).

**α-Complementation Assay**

Yeast cells were transformed with plasmids encoding various α fusion proteins and with pαp, pαmp, or pαNLS. Colonies were streaked on X-gal plates and incubated at 30 °C for 72 h.

**Protein Purification for Edman Degradation**

Induced yeast cultures were grown to 1.5 A at 600 nm. Cells were lysed with glass beads in Buffer A (6 M guanidine hydrochloride, 0.1 M NaH2PO4, 10 mM Tris, pH adjust to 8 with NaOH). Purification proceeded according to Qiagen protocol of nickel-nitrilotriacetic acid-Sepharose (Qiagen). Purification quality was assessed with Coomassie Blue SDS-PAGE staining. The purified protein was subjected to an Edman degradation analysis.

**RESULTS**

**Nfs1 Is Processed by Two Peptidases, MPP and the Novel Icp55—**

Nfs1 is a highly conserved mitochondrial cysteine desulfurase in all organisms. In *S. cerevisiae* and in other eukaryotes the protein harbors a typical N-terminal MTS and is localized to the mitochondria. As outlined in the introduction, a low abundant form of Nfs1 in the nucleus may be targeted by a nuclear localization sequence (NLS) (6, 9). To characterize the Nfs1 distribution mechanism, one of our first efforts was to identify its exact MTS and determine the MPP-cleavage site at the N terminus of Nfs1. Nfs1 fused to a six-histidine tag was purified from a wild-type (WT) yeast strain and was subjected to Edman degradation analysis. The N-terminal sequence detected was PAAGVKLDD, indicating that Nfs1 is cleaved between two proline residues at positions 36 and 37 (Fig. 1A).

The detected cleavage site according to this Edman degradatory analysis was unexpected, because typical MPP cleavage sites usually include arginine residues at one or more of the positions −2, −3, and/or −10 relative to the cleavage site (19, 20). In fact, cleavage between phenylalanine 33 and tyrosine 34 would place arginines at positions −2 and −3 relative to this site according to the MPP preferences, referred to above (see highlighted arginines at positions −2 and −3 relative to this cleavage site in Fig. 1A). Another prediction based on the bioinformatic MitoProtII program (21, 22), places the cleavage site for yeast Nfs1 between tyrosine 34 and serine 35 (arginines would be at positions −2 and −10 relative to this cleavage site).

Thus, we hypothesized the existence of an additional proteolytic step (besides that performed by MPP), which cleaves Nfs1 immediately downstream of the predicted MPP cleavage site. This could result in the N-terminal sequence deduced by Edman degradation of Nfs1 (between proline 36 and proline 37). We screened yeast databases (*Saccharomyces Genome Database* and *Yeast Proteome Database*) for known and putative mitochondrial proteases. We were particularly interested in enzymes with aminopeptidase activity, that could theoretically remove between two and three amino acids. Among the candidate enzymes we found a group of putative Xaa-Pro aminopeptidases that presumably remove Xaa-Pro from the N terminus of substrate proteins. Only one putative Xaa-Pro aminopeptidase, Icp55 (*YER078c*), was predicted to be localized in the mitochondria according to the databases.

To directly examine if Nfs1 is a substrate of Icp55, Western blot analysis was performed on extracts of yeast cells harboring a deletion of the *ICP55* gene (*Δicp55*) in comparison with WT strains. Nfs1, from the *Δicp55* strain exhibited a slightly slower migrating band, indicating a higher molecular weight than the corresponding protein band from WT strains (Fig. 1B). Edman degradation analysis performed on Nfs1 purified from the knockout strain, *Δicp55*, detected three additional amino acids, •...
YSP, at the N terminus of Nfs1 (Fig. 1A). Thus, Nfs1 is subjected to two steps of processing: first by MPP, which cleaves the precursor between phenylalanine 33 (Phe-33) and tyrosine 34 (Tyr-34), and second by a newly discovered processing enzyme, Icp55, which cleaves between proline 36 (Pro-36) and proline 37 (Pro-37) removing three amino acids residues (YSP).

To investigate the properties of the novel peptidase, we first examined whether Icp55 can cleave the full-length Nfs1 precursor (i.e. the unprocessed form). A mutant MPP recognition sequence was constructed by replacing the two arginine codons at positions −2 and −3, which are expected to prevent cleavage by MPP (Fig. 1C). As anticipated, the mutant precursor migrated on SDS-PAGE according to a molecular weight of the Nfs1 precursor (Fig. 1D, compare lanes 2 and 3). This indicates that, in the absence of Nfs1 processing by MPP, the Nfs1 precursor is not cleaved by Icp55, because we can only detect the full-length Nfs1 precursor. Thus, Icp55 is in fact a mitochondrial processing enzyme whose recognition sequence is exposed only after removal of the MTS by MPP.

To gain insight into the requirements for Icp55 processing we changed the amino acid sequence in the vicinity of the Icp55 cleavage site. Each mutant protein was subjected to Edman degradation following expression in both the WT strain (expressing endogenous Icp55) and in the chromosomal knockout strain, Δicp55 (Fig. 1C). Only in one case, replacement of two prolines (Pro-36 and Pro-37) by two asparagines, was the cleavage prevented by Icp55. These two prolines seem to be of importance for the Icp55 cleavage reaction, because the replacement of a single proline changed the specificity to a new cleavage site without eliminating the cleavage reaction per se (Fig. 1C). Replacement of the first proline (Pro-36) by alanine moved the cleavage site between Tyr-34 and Ser-35, whereas exchange of the second (Pro-37) by alanine moved the cleavage between residue Ser-35 and Pro-36 (Fig. 1C). Another residue that we thought may be of importance is the N-terminal tyrosine exposed by MPP cleavage. Replacement of Tyr-34 by a phenylalanine had no effect on Icp55 cleavage between the prolines (Pro-36 and Pro-37) while its exchange by leucine brought about incomplete cleavage at the same site. Possibly an aromatic residue at this position may be of significance. Replacement of Ser-35 by alanine did not prevent cleavage but also moved the cleavage site between Tyr-34 and Ala-35 (Fig. 1C). These data clearly show that changing amino acids in the vicinity of the cleavage site affect cleavage efficiency and/or the specific site cleaved. The specificity of Icp55 cleavage remains to be identified.

Detection of Nfs1 in Mitochondria and the Nucleus—There are a number of studies that suggest a nuclear function for yeast Nfs1 (5–7), however, due to the minute amounts of the protein in the nuclear fraction these data are indirect. The difficulty in detection prompted us to employ our α-complementation assay, which has been previously shown to be a sensitive in vivo approach for detecting eclipsed distributed proteins (1, 16). The α-complementation is based on the ability of two artificially expressed peptide fragments of Escherichia coli β-galactosidase (designated α77 amino acids and ω993 amino acids) to assemble in vivo into an enzymatically active complex only when present in the same compartment (16) (Fig. 2A). We fused the α fragment of β-galactosidase to the C terminus of Nfs1 (Nfs1-α) and expressed this fusion protein in yeast, whereas the ω polypeptide was expressed either in the cytosol (ωc), mitochondria (ωm), or nucleus (ωNLS). Although ωc and ωm have been described previously (16), ωNLS is described for the first time here as a way to get an indication of nuclear localization. To create ωNLS−, we attached the NLS of SV-40 T-Antigen (PKKKRKV) (17) to the C terminus of the ω fragment. We have performed subcellular
Nfs1 Distribution and Its Processing Enzyme, Icp55

FIGURE 3. The NFS1 gene encodes a single gene product. A, metabolic labeling of wild-type strains expressing Nfs1 or Nfs1-α was performed in the absence or presence of CCCP (membrane potential uncoupler). p, precursor; m, mature. B, schematic representation of Nfs1 mutants. Gray and black boxes represent the MTS and mature sequences, respectively, curved arrows represent the potential translation initiation sites. Nfs1-M85L mutant protein contains a missense mutation in which Met-85 was changed to Leu. Nfs1-Shift has an additional nucleotide (C) inserted between the first and second AUG that causes early termination of translation starting from the first AUG. C, the Tet-NFS1 strain expressing the various Nfs1 mutant proteins were examined for growth on YPD plates in the presence or absence of tetracycline (Tet). D, Western blot analysis of the Tet-NFS1 strain expressing the mutant proteins above. The cells were grown on galactose media containing tetracycline for 8 h. Hsp60 antibody was used to control equivalent loading.

fractionation and can show that the ω_{NLS} fusion protein exhibits a significant presence in the nucleus (data not shown).

The first step in using the Nfs1-α fusion protein for analysis of Nfs1 distribution was to show that the apparent characteristics of the fusion protein are identical to those of the wild-type protein. Described below are the fusion protein’s enzymatic activity in vivo (Fig. 2B), subcellular distribution (Fig. 2C), and processing in mitochondria (Fig. 3A). The Nfs1-α fusion protein can complement the Nfs1 activity in the Tet-NFS1 strain (Fig. 2B). This yeast strain contains a Tet-off promoter upstream of the endogenous NFS1 gene and can be repressed by adding tetracycline to the medium (14). The Tet-NFS1 strain expressing an empty vector does not grow on YPD plates containing tetracycline (Tet). Alternatively, we show that an exclusive mitochondrial protein fused to the Nfs1-α fragment (Kgd2-α (dihydrolipoyl transsuccinylase, a component of the mitochondrial ζ-ketoglutarate dehydrogenase complex), produces non-colored colonies when coexpressed with ω_{NLS} or with ω_{m}, but not with with the ω fragment (Fig. 2D). These results indicate that a subpopulation of the Nfs1-α molecules is located in the nucleus and in fact no Nfs1-α is present in the cytosol (Fig. 2D), providing direct evidence for the dual distribution of this protein. As a negative control, we show that an exclusive mitochondrial protein fused to the α fragment of Kgd2-α (dihydrolipoyl transsuccinylase, a component of the mitochondrial ζ-ketoglutarate dehydrogenase complex), produces non-colored colonies when coexpressed with ω_{NLS} or with ω_{c} (Fig. 2D). The α-fragment itself, however, when attached to NLS as a positive control, produces blue colonies exclusively when coexpressed with the nuclear ω fragment (Fig. 2D). The cytosolic control HxK1-α fusion protein (HxK1 fused to α) produces blue colonies when coexpressed with the NLS not with ω_{c} but also with ω_{NLS}. This result is due to incomplete localization of ω_{NLS} to the nucleus, and a subtraction of it remains in the cytosol. As a consequence, blue colonies appear for cells coexpressing ω_{NLS} and any cytosolic
protein fused to the α fragment. In this regard, because Nfs1-α
is not a cytosolic protein (white colonies with α), blue colonies
with ωNLS obviously detect the nuclear localization of the
protein.

In support of this analysis a Nfs1-α mutant, lacking the MTS
(ΔMTS-Nfs1-α), as expected, appears to be located in the
nucleus but not in mitochondria. Surprisingly, ΔMTS-Nfs1-α
appeared to also be in the cytosol, suggesting that the nuclear
import of ΔMTS-Nfs1-α is somehow saturated, which in turn
may suggest the participation of currently unknown factors in
this process.

In addition, we mutated the NLS sequence of Nfs1-α simi-
larly (not identically) to that described by Nakai and coworkers
(6) from RRRPR to GGGR (designated Nfs1-mutNLS-α), which
prevents the targeting of the protein to the nucleus. As
shown in Fig. 2C mutant Nfs1-mutNLS-α is exclusively located
in mitochondria and is absent from the nucleus and cytosol
(Fig. 2D). Thus, we conclude that Nfs1 is dual targeted between
the mitochondria and nucleus, and it appears that both the NLS
and the MTS are required for this dual localization.

Yeast Nfs1 Is a Dual Localized, Single Translation Product—
There are various mechanisms by which the same protein can
be localized to more than one subcellular compartment. In one
possible mechanism two translation products are made, one
harboring and one lacking a targeting signal (23, 24). An alter-
native dual targeting mechanism involves a single translation
product which, nevertheless, distributes between two compart-
ments. To detect the Nfs1 precursor(s) in comparison to the
mature protein, we performed metabolic labeling of yeast cells
in which import of proteins was blocked by the membrane
potential uncoupler CCCP. If there are two Nfs1 translation
products, we should expect two bands when the import to the
mitochondria is blocked by CCCP, corresponding to an MTS
(higher and lower molecular weights, respectively). However, in
the presence of CCCP only the precursor (p) form of the protein
appeared for both Nfs1 and Nfs1-α (Fig. 3A, compare lanes 1 to
2 and 3 to 4), which is consistent with a single Nfs1 gene prod-
uct. This obviously does not rule out the possibility that a sec-
ond translation product (nuclear derivative) is not detected,
because it is made in minute amounts.

To address this question of a low abundance single transla-
tion product we generated a Nfs1 mutant in which the second
AUG, the only alternative in-frame initiation codon, was
mutated to UUG (changing the methionine codon 85 to
leucine, Nfs1-M85L, Fig. 3B). As shown in Fig. 3C, the Nfs1-
M85L mutant protein readily grows on tetracycline-containing
YPD plates like the wild-type Nfs1 (compare seventh and eighth
rows), indicating that the single translation product (starting at
the first AUG) is giving rise to both the mitochondrial and the
nuclear protein. As a control we created a frameshift mutation
(nucleotide insertion of C) between the first and the second
AUGs, preventing meaningful translation from the first AUG of
NFS1, but this should not effect translation from the second
AUG (Met-85, Fig. 3B). This Nfs1-Shift mutant as expected
could not grow in the presence of tetracycline (Fig. 3C, ninth
row) due to the absence of mitochondrial Nfs1. However, if
translation initiation from the second AUG (Met-85), enabling
nuclear Nfs1 targeting, actually exists in vivo, one should be
able to fully complement this activity with exclusive mitochon-
drial Nfs1. To address this question we used the exclusive mito-
ochondrial Nfs1-mutNLS mutant as described earlier. Cells
harboring plasmids encoding both the mitochondrial (Nfs1-
mutNLS) and nuclear (ΔMTS-Nfs1)-targeted versions can in
fact grow on tetracycline plates (Fig. 3C, right panel fifth row).
However, strains co-expressing Nfs1-shift and Nfs1-mutNLS
could not grow on tetracycline plates (Fig. 3C), indicating that
Nfs1 is not translated from the second AUG and thus cannot
complement the Nfs1 nuclear function. Consistently, no
expression of Nfs1-shift was detected by Western blot (Fig. 3D,
fourth lane). These results suggest that yeast NFS1 encodes a
single, full-length translation product, which distributes
between the mitochondria and nucleus.

Nuclear Nfs1 Is Processed by MPP—What is the mechanism
by which the single Nfs1 translation product is dual localized in
yeast? Two scenarios are possible: First, the precursor may be
efficiently targeted to mitochondria, but a small fraction of
molecules could, after being processed by MPP, move back by
reverse translocation into the cytosol. In this case the nuclear
protein should be processed, thus lacking the MTS. Such a
mechanism resembles the previously described dual localiza-
tion of fumarase andaconitate in yeast (1, 23–28). In the second
scenario, some precursor Nfs1 molecules never reach the mito-
chondria and are directly targeted from the cytosol to the
nucleus (2, 5). A somewhat similar mechanism has been
described for the protein Adk1 in its distribution between the
cytosol and mitochondria (29). The nuclear fraction according
to this mechanism should contain the full-length Nfs1 precur-
sor, including the MTS. To distinguish between these possi-
bilities, we asked whether the precursor of Nfs1 can be functional
in the nucleus. As described in the previous sections we have
mutated the Nfs1 MPP cleavage site (Fig. 1A), which results in
the expression of an unprocessed form of Nfs1 (Nfs1-UP). As
shown in Fig. 1D, the processing of Nfs1-UP-α was examined by
metabolic labeling in the presence (+) or absence (−) of CCCP.
For Nfs1-UP we detected identical precursor size bands in the
presence and absence of the uncoupler (see differences in size
for Nfs1-α and no change for the Nfs1-UP-α mutant).

The activity of the Nfs1-UP mutant protein in vivo was ana-
lyzed in the conditional yeast Tet-NFS1 strain. This strain
expressing the Nfs1-UP mutant protein did not show growth in
the presence of tetracycline (Fig. 4, right panel). To examine
whether the Nfs1-UP mutant is inactive in the nucleus, we used
the Nfs1-mutNLS. We found that Nfs1-UP cannot comple-
ment Nfs1-mutNLS for growth of the Tet-NFS1 strain (Fig. 4,
left panel last row), indicating that the Nfs1-UP mutant protein

FIGURE 4. The unprocessed Nfs1 mutant is inactive in the nucleus. The
Tet-NFS1 cells expressing the indicated Nfs1 mutant proteins were grown on
YPD plates in the presence or absence of tetracycline (Tet).
**Nfs1 Distribution and Its Processing Enzyme, Icp55**

is inactive in the nucleus. Based on these findings we propose that Nfs1 needs to be processed by MPP to be functional in the nucleus. These data support a mechanism that involves reverse translocation of processed Nfs1, i.e. the retrograde movement of Nfs1 (first scenario above).

To gain additional support for the notion that the Nfs1 nuclear form is processed, a WT culture overexpressing Nfs1-α under the GAL10 promoter was subjected to a nuclear subcellular fractionation experiment. The nuclear fraction (N) was concentrated 24-fold more than the total cell extract (T), and aliquots were analyzed by Western blotting. The quality of the fractionation was monitored by antibodies against nuclear (histone acetyl H4), mitochondrial (Hsp60, Fumarase), and cytosolic (Hexokinase1, Fumarase) markers (Fig. 5). Nuclear Nfs1-α displays an apparent molecular weight that is indistinguishable from the mature mitochondrial form detected in the total cell extract and markedly differs from the precursor size (Fig. 5, compare the Nfs1-α in the first and second lanes to the third and fourth lanes). Taken together, these results strongly support a mechanism in which the nuclear Nfs1 is partially translocated into mitochondria (N terminus), and, after processing by MPP, undergoes a retrograde movement back into the cytosol and then the nucleus.

**Icp55-α Distributes Like Its Substrate, Nfs1, between Mitochondria and the Nucleus**—In this study we have shown that the protein Nfs1 is dual localized and that it is a substrate of a novel processing enzyme, Icp55. We asked whether Icp55 is also dual localized to the mitochondrial and nucleus like its substrate, Nfs1. Again, our α-complementation assay was employed and blue colonies appeared only when Icp55-α was co-expressed with mitochondrial or nuclear localized ω fragment but not with the cytosolic ω fragment (Fig. 6A, top row). This distribution pattern resembles the pattern of Nfs1-α. The Icp55 sequence was scanned for potential nuclear localization signals. Because we did not find any consensus sequence similar to that of T-antigen NLS or the bipartite NLS of the nucleoplasmin (30, 31), we searched for regions enriched in positively charged amino residues (32). As shown in Fig. 6B, a region of positively charged amino acid residues (underlined and enlarged in Fig. 6B) was detected and subsequently deleted (42 amino acids between Lys-234 and Arg-276), creating a mutant that presumably lacks a putative NLS (Icp55-ΔNLS-α). This mutant was also subjected to the α-complementation assay and, in contrast to the wild type Icp55, it exhibited a blue colony phenotype only when expressed with the mitochondrial ω fragment and not when expressed with the nuclear ω fragment (Fig. 6B, lower row). These results indicate that the Icp55 “NLS” mutant was not targeted to the nucleus and, furthermore, supports the notion that Icp55 is also a dual distributed protein between mitochondria and nucleus. Thus, cleavage of the three residues YSP might occur in the nucleus.

**DISCUSSION**

In this study we provide insight into the distribution process of the yeast enzyme Nfs1 between mitochondria and the nucleus. Previously, Nakai and co-workers showed evidence that suggested that Nfs1 is also localized to the nucleus based on an NLS-like sequence they detected. Here, we present physical evidence for Nfs1 dual localization. First, we demonstrate that Nfs1-α is associated with ω fragment both in the nucleus and in the mitochondria, but not in the cytosol. Mutations in the NLS sequence eliminate the association of the two fragments, α and ω, in the nucleus. In addition, subcellular fractionation clearly detects overproduced Nfs1 in the nucleus. This enzyme is, in fact, dual localized in an “eclipsed” distribution pattern with the majority of the protein in mitochondria and a minute amount in the nucleus.

With respect to the mechanism of Nfs1 distribution, the results presented in this study are consistent with a single translation product of this protein giving rise to both localizations: (i) elimination of the second potential translation initiation codon (Nfs1-M85L) exhibited full functional complementation; (ii) a frameshift mutation between the first AUG (translation initiation codon) and the second AUG (Nfs1-shift) did not provide a functional nuclear Nfs1; (iii) only one protein species corresponding to the precursor was detected when processing by MPP was prevented and only the mature protein was detected (also in the nucleas) when processing was permitted; and (iv) the NFS1 gene in many eukaryotes does not contain any alter-
native start codons at the N terminus, which may encode alternative functional Nfs1 derivatives (5). In contrast, the human nuclear form of Nfs1 was suggested to be produced by alternative translation initiation (11). Our results suggest that a single Nfs1 translation product is generated in yeast, which is then distributed between the mitochondria and nucleus.

What is the precise mechanism of Nfs1 targeting and subcellular distribution? Our data show that nuclear Nfs1 depends on MPP processing for function and, hence, suggest that this isoform may first be translocated into mitochondrial matrix prior to its targeting and import into the nucleus guided by the internal NLS. There is no evidence for an export mechanism of matrix-located proteins out of the organelle. One possible mechanism, that could explain the data, involves reverse translocation and was first described for the tricarboxylic acid cycle enzyme, fumarase (18, 25, 27, 28, 33). According to this mechanism, the extramitochondrial localization is achieved by retrograde movement of processed protein (MTS removed by MPP) through the TOM and TIM23 translocation channels back to the cytosol during translocation. This mechanism involves only partial import of the N terminus of the protein into the mitochondrial matrix prior to reverse translocation. Nuclear localization of Nfs1 involving reverse translocation is supported by several findings indicating that this isoform was produced as a precursor with an MTS, which then was removed as follows. (i) Unprocessed Nfs1 cannot complement nuclear activity in a strain deleted for Nfs1, whereas a version of the protein lacking the MTS can complement the Nfs1 nuclear function. This rules out the possibility that Nfs1 that is not initially targeted to the mitochondria as a precursor is functional in the nucleus. (ii) The mitochondrial and nuclear Nfs1 isoforms are generated from one single product (see above). (iii) Subcellular fractionation detects nuclear Nfs1 at a molecular weight precisely corresponding to the mature protein. Thus, removal of the MTS by MPP from the Nfs1 single translation product requires at least partial translocation of the N terminus into mitochondria. Moreover, following a block in mitochondrial protein import (by CCCP), we can only detect the precursor form of Nfs1, which indicates there is no other processing enzyme outside mitochondria, which can remove the MTS from the nuclear Nfs1. Because there is no evidence for export of proteins out of mitochondrial matrix (as mentioned earlier), the only known mechanism that can enable mitochondrially processed proteins to leave mitochondria is reverse translocation of a translocation intermediate spanning both import channels. According to this mechanism all of the Nfs1 precursor molecules are first partially targeted to the mitochondria and, after removal of the MTS by MPP, a small fraction still spanning the membranes moves back and is then targeted to the nucleus. We currently do not know the driving force for reverse translocation of Nfs1 back through the mitochondrial membranes. This could be, among other possibilities, the specific folding traits of the protein that block forward movement as in the case of fumarase (26, 27) or the specific N-terminal amino acid sequence of Nfs1 that causes inefficient binding between the motor mtHsp70 and the mature Nfs1, allowing a “slippage” of some of the protein molecules back into the cytosol.

A second topic of our study is the description of the novel mitochondrial processing enzyme, Icp55. We show that Nfs1 undergoes a two-step processing in the mitochondrial matrix; by MPP and then by a new peptidase, Icp55, which removes three amino acids, YSP from Nfs1 after MPP cleavage. Known processing peptidases in mitochondria include the following: (i) MPP, mentioned above, which is a conserved hetero-dimeric metallopeptidase that cleaves off sorting sequences in the matrix space (34); (ii) the MIP, which is a monomeric metallopeptidase that removes an octapeptide from preproteins after their processing by MPP (34); (iii) the inner membrane peptidase is a heterotrimeric complex that is located within the inner membrane (34) and cleaves several nuclearly encoded proteins in the intermembrane space after they have first been cleaved by MPP in the matrix (34); and (iv) a number of proteases, including AAA proteases, Rhomboid protease Pcp1, and the metalloprotease Atp23 that perform specific processing events (34). The physiological role of the different processing enzymes is not always understood; however, severe phenotypes upon gene inactivation suggest that they have important functions. Icp55 joins this important list of processing peptidases.

Based on domain homology, Icp55 was suspected to be an X-Pro aminopeptidase (EC 3.4.11.9), which catalyzes the release of any N-terminal amino acid that is linked with proline (NCBI, Conserved Domain Data base, CDD family no. cd01085). This description does not fit the observed Icp55 cleavage reactions for both the Nfs1 wild-type and mutant N termini as determined by sequential Edman degradation. Although proline appeared to be important for the overall processing reaction, this residue does not have to be located at the +2 position (relative to the MPP cleavage site) as would be expected for an X-Pro aminopeptidase. The prolines in Nfs1 are located further in, at positions +3 and/or +4. Furthermore, exchange of only one of these prolines did not fully abolish cleavage. In this regard, Icp55 exhibits similar characteristics to the other mitochondrial processing peptidases referred to above suggesting that this peptidase exhibits rather low sequence specificity. Moreover, our data show that Icp55 can cleave Nfs1 only after MPP processing has occurred, similarly to MIP and inner membrane peptidase. What is the physiological importance of cleavage by Icp55? Cleavage by Icp55 can change the N-terminal amino acid, which for example can affect the characteristics of the protein and/or its stability. For Nfs1 cleavage by MPP exposes Tyr at the N terminus, whereas the secondary cleavage by Icp55 exposes Pro at the N terminus. We assume that Icp55 has additional substrates in the mitochondria and the nucleus besides Nfs1 and may have a wide range of effects under specific conditions.

The α-complementation assay in combination with a preliminary mutational analysis intriguingly suggest that Icp55 may also be a dual distributed protein located in the same compartments as its Nfs1 substrate, the mitochondria, and nucleus. Whether Icp55 processes Nfs1 before it moves back into the cytosol or whether processing by Icp55 occurs in the nucleus remains to be determined. At present due to the low levels of nuclear Nfs1 it is impossible to subject nuclear Nfs1 to standard biochemical analysis. Whether these preliminary findings define a general concept of protein targeting, in
that combinations of proteins that interact with one another are identically dual targeted to the same organelles, remains to be explored.

Acknowledgments—We thank Ariel Gaaton (Hebrew University of Jerusalem) for Edman degradation. Special thanks to Yudit Karp for dedicated assistance.

REFERENCES
1. Regev-Rudzki, N., Karniely, S., Ben-Haim, N. N., and Pines, O. (2005) Mol. Biol. Cell 16, 4163–4171
2. Regev-Rudzki, N., and Pines, O. (2007) BioEssays 29, 772–782
3. Shlevin, L., Regev-Rudzki, N., Karniely, S., and Pines, O. (2007) Traffic 8, 169–176
4. Zheng, L., White, R. H., Cash, V. L., Jack, R. F., and Dean, D. R. (1984) Proc. Natl. Acad. Sci. U.S.A. 90, 2754–2758
5. Mühlhoff, U., Balk, J., Richhardt, N., Kaiser, J. T., Sipos, K., Kispal, G., and Lill, R. (2004) J. Biol. Chem. 279, 36906–36915
6. Nakai, Y., Nakai, M., Hayashi, H., and Kagamiyama, H. (2001) J. Biol. Chem. 276, 8314–8320
7. Nakai, Y., Umeda, N., Suzuki, T., Nakai, M., Hayashi, H., Watanabe, K., and Kagamiyama, H. (2004) J. Biol. Chem. 279, 12363–12368
8. Nakai, Y., Nakai, M., Lill, R., Suzuki, T., and Hayashi, H. (2007) Mol. Cell Biol. 27, 2841–2847
9. Kispal, G., Csere, P., Prohl, C., and Lill, R. (1999) EMBO J. 18, 3981–3989
10. Nakai, Y., Yoshihara, Y., Hayashi, H., and Kagamiyama, H. (1998) FEBS Lett. 433, 143–148
11. Land, T., and Rouault, T. A. (1998) Mol. Cell 2, 807–815
12. Fosset, C., Chauveau, M. J., Guillon, B., Canal, F., Drapier, J. C., and Bouton, C. (2006) J. Biol. Chem. 281, 25398–25406
13. Kambacheld, M., Augustin, S., Tatsuta, T., Müller, S., and Langer, T. (2005) J. Biol. Chem. 280, 20132–20139
14. Mnaimneh, S., Davierwala, A. P., Haynes, J., Moffat, J., Peng, W. T., Zhang, W., Yang, X., Pootoolal, J., Chua, G., Lopez, A., Trochesset, M., Morse, D., Krogon, N. J., Hiley, S. L., Li, Z., Morris, Q., Grigull, J., Mitsakakis, N., Roberts, C. J., Greenblatt, J. F., Boone, C., Kaiser, C. A., Andrews, B. J., and Hughes, T. R. (2004) Cell 118, 31–44
15. Munberg, D., Müller, R., and Funk, M. (1994) Nucleic Acids Res. 22, 5767–5768
16. Karniely, S., Rayzen, A., Sass, E., and Pines, O. (2006) Exp. Cell Res. 312, 3835–3846
17. Lanford, R. E., Kanda, P., and Kennedy, R. C. (1986) Cell 46, 575–582
18. Knox, C., Sass, E., Neupert, W., and Pines, O. (1998) J. Biol. Chem. 273, 25587–25593
19. Ito, A. (1999) Biochem. Biophys. Res. Commun. 265, 611–616
20. Niidome, T., Kitada, S., Shimokata, K., Ogishima, T., and Ito, A. (1994) J. Biol. Chem. 269, 24719–24722
21. Andreoli, C., Prokisch, H., Hortnagel, K., Mueller, J. C., Munsterkotter, M., Scharfe, C., and Meitinger, T. (2004) Nucleic Acids Res. 32, D459–D462; database issue
22. Prokisch, H., Andreoli, C., Ahting, U., Heiss, K., Ruepp, A., Scharfe, C., and Meitinger, T. (2006) Nucleic Acids Res. 34, D705–D711; database issue
23. Danpure, C. J. (1995) Trends Cell Biol. 5, 230–238
24. Karniely, S., and Pines, O. (2005) EMBO Rep. 6, 420–425
25. Regev-Rudzki, N., Yogev, O., and Pines, O. (2008) J. Cell Sci. 121, 2423–2431
26. Sass, E., Blachinsky, E., Karniely, S., and Pines, O. (2001) J. Biol. Chem. 276, 46111–46117
27. Sass, E., Karniely, S., and Pines, O. (2003) J. Biol. Chem. 278, 45109–45116
28. Yogev, O., Karniely, S., and Pines, O. (2007) J. Biol. Chem. 282, 29222–29229
29. Schricker, R., Angermayr, M., Strobel, G., Klinke, S., Korber, D., and Bandlow, W. (2002) J. Biol. Chem. 277, 28757–28764
30. Dingwall, C., Robbins, J., Dilworth, S. M., Roberts, B., and Richardson, W. D. (1988) J. Cell Biol. 107, 841–849
31. Kalderon, D., Richardson, W. D., Markham, A. F., and Smith, A. E. (1984) Nature 311, 33–38
32. Makkerh, J. P., Dingwall, C., and Laskey, R. A. (1996) Curr. Biol. 6, 1025–1027
33. Karniely, S., Regev-Rudzki, N., and Pines, O. (2006) J. Mol. Biol. 358, 396–405
34. Koppen, M., and Langer, T. (2007) Crit. Rev. Biochem. Mol. Biol. 42, 221–242